In this exploratory analysis from KEYNOTE-671, researchers examined event-free survival in NSCLC patients who received perioperative pembrolizumab but did not achieve a pCR.
To address the limitations of binary pCR classification, Pusztai and colleagues developed the residual cancer burden (RCB) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results